4-amino-N-(2-ethylhexyl)benzenesulphonamide

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1975-12-15 to 1977-06-07

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: scientifically acceptable study report

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1977

Report date:

1977

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

other: according to BASF-internal standard

Test guideline 2

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

4-amino-N-(2-ethylhexyl)benzenesulphonamide

EC Number:

258-799-9

EC Name:

4-amino-N-(2-ethylhexyl)benzenesulphonamide

Cas Number:

53817-09-7

Molecular formula:

C14H24N2O2S

IUPAC Name:

4-amino-N-(2-ethylhexyl)benzene-1-sulfonamide

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: males 200 g, females 160 g
- Diet: The animals were offered a standardized animal laboratory diet Altromin R 1324 (Altromin GmbH, Lage, Germany)

IN-LIFE DATES: From: 1977-06-29 To: 1977-07-13

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

CMC (carboxymethyl cellulose)

Remarks:

Suspension in 0.5% aqueous CMC preparation with 2 - 3 drops Cremophor EL

Details on oral exposure:

VEHICLE
- Concentration in vehicle: Test concentration used: 10 % and 15 % (G/V)
- Amount of vehicle (if gavage): dose level 1000 mg/kg bw 1.13 mL; dose level 4640 mg/kg bw 5.26 mL

MAXIMUM DOSE VOLUME APPLIED: males: 30.9 mL/kg bw

DOSAGE PREPARATION: Suspension in 0.5% aqueous CMC preparation with 2 - 3 drops Cremophor EL

Doses:

1000 and 4640 mg/kg (due to technical reasons, higher concentrations and thereby higher dose levels could not be administered)

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Other examinations performed: clinical signs, body weight
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: normal weight development reported
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs (dyspnoe, apathy, dorsal or lateral position, tumbling, atony, narcotic-like state, spasmodic behaviour, tonic spasms, lacrimation, poor general condition, skin/fur, tremor, feces, urine)

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 4 640 mg/kg bw

Based on:

test mat.

Effect levels 2

Sex:

male/female

Dose descriptor:

LD0

Effect level:

>= 4 640 mg/kg bw

Based on:

test mat.

Mortality:

none

Clinical signs:

other: no adverse effects reported

Gross pathology:

no abnormal observations